Programs and Pipeline

Using our proprietary SAMiRNA prodrug platform technology, Bioneer is currently advancing clinical development of pipeline programs for previously non-druggable targets, including cancer, COPD, liver fibrosis, and antivirals, internally with our research and development resources as well as through partnerships with major global pharmaceutical companies.


  • A member of the inhibitor of apoptosis (IAP) family
  • Functions to inhibit caspase activation, leading to the inhibition of apoptosis
  • Disruption of Survivin expression leads to decrease in tumour growth
  • Expressed highly in most human tumors including breast and colon cancers
  • But, completely absent in terminally differentiated cells, making Survivin an ideal target for cancer therapy
  • Also expressed in circulating tumor cells (CTCs), which are associated with malignancies and metastasis
  • Disruption of Survivin pathway treatment of metastasis and for prevention of tumor recurrence from various cancers

©2010 Bioneer Corporation